Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
StockStory.org on MSN
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively ...
Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF ...
While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback